212 related articles for article (PubMed ID: 28097096)
1. Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels.
Schicho A; Hellerbrand C; Krüger K; Beyer LP; Wohlgemuth W; Niessen C; Hohenstein E; Stroszczynski C; Pereira PL; Wiggermann P
J Clin Transl Hepatol; 2016 Dec; 4(4):288-292. PubMed ID: 28097096
[No Abstract] [Full Text] [Related]
2. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9.
Minici R; Ammendola M; Manti F; Siciliano MA; Minici M; Komaei I; Currò G; Laganà D
Front Pharmacol; 2021; 12():634087. PubMed ID: 33897422
[TBL] [Abstract][Full Text] [Related]
4. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
5. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
6. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
7. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
Qian J; Oppermann E; Tran A; Imlau U; Qian K; Vogl TJ
World J Gastroenterol; 2016 Jun; 22(21):5042-9. PubMed ID: 27275096
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.
Chang PY; Huang CC; Hung CH; Yu CY; Wu DK; Hwang JI; Liang PC; Wu RH; Tsai WL; Lin YJ; Liu YS; Liang HL; Lee RC; Chen CH
Liver Cancer; 2018 Oct; 7(4):312-322. PubMed ID: 30488021
[TBL] [Abstract][Full Text] [Related]
10. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy.
Schicho A; Pereira PL; Haimerl M; Niessen C; Michalik K; Beyer LP; Stroszczynski C; Wiggermann P
Oncotarget; 2017 Sep; 8(42):72613-72620. PubMed ID: 29069813
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
[TBL] [Abstract][Full Text] [Related]
13. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Song MJ; Chun HJ; Song DS; Kim HY; Yoo SH; Park CH; Bae SH; Choi JY; Chang UI; Yang JM; Lee HG; Yoon SK
J Hepatol; 2012 Dec; 57(6):1244-50. PubMed ID: 22824821
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
[TBL] [Abstract][Full Text] [Related]
15. The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE).
Leelawat K; Laisupasin P; Kiatdilokrut A; Pongtongpool T; Narong S; Samkhumphim N; Ket-Horm S
J Med Assoc Thai; 2008 Oct; 91(10):1539-43. PubMed ID: 18972897
[TBL] [Abstract][Full Text] [Related]
16. Degradable Starch Microspheres Transarterial Chemoembolization with or without Lipiodol for Liver Metastases from Pancreatic Cancer: A Prospective Randomized Trial.
Vogl TJ; Lilienthal C; Gruber-Rouh T; Afraz Z; Adwan H
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958413
[TBL] [Abstract][Full Text] [Related]
17. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.
Li X; Feng GS; Zheng CS; Zhuo CK; Liu X
World J Gastroenterol; 2004 Oct; 10(19):2878-82. PubMed ID: 15334691
[TBL] [Abstract][Full Text] [Related]
18. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
Poon RT; Lau C; Yu WC; Fan ST; Wong J
Oncol Rep; 2004 May; 11(5):1077-84. PubMed ID: 15069550
[TBL] [Abstract][Full Text] [Related]
19. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
[TBL] [Abstract][Full Text] [Related]
20. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
